BIIB
reuters.dev
http://www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FBIIB.O%2Fkey-developments%2Farticle%2F2715198&ei=oIaaUqDjE4qw0AGZAw&usg=AFQjCNE8jtdW2YzmgGZ7TpG4Lc4HGkKRBQ
Biogen Idec Inc And Elan Corporation, plc Announces Results From Several Studies Of TYSABRI
Tuesday, 19 Mar 2013 03:00am EDT
Biogen Idec Inc and Elan Corporation, plc announced results from several studies of TYSABRI (natalizumab) that demonstrate its efficacy compared to other multiple sclerosis (MS) treatments, provide additional data supporting anti-JC virus (JCV) antibody status stability, and suggest better outcomes when progressive multifocal leukoencephalopathy (PML) is detected early. These data will be presented at the 65th Annual Meeting of the American Academy of Neurology (AAN) in San Diego. The results indicate that relapses were not only more likely to occur in patients taking IFN and GA, but that they occurred more quickly, when compared to patients taking TYSABRI (hazard ratio 2.73, 95% confidence interval 2.10-3.55, p
